Hospital

The ACACIA-HCM trial marks the first time a therapy has shown statistically significant improvements in exercise capacity and symptom burden in patients with non-obstructive hypertrophic cardiomyopathy.

Health systems are being pushed to fundamentally rethink how to support medication safety, regulatory compliance, and patient care with fewer resources.

Ketamine, an NMDA receptor antagonist, is increasingly being used in low-dose infusions as a multimodal, opioid-sparing strategy for patients with refractory acute and chronic pain.

Outpatient infusion and specialty pharmacy pharmacists drive safe, cost-effective oncology and chronic-care expansion, from biosimilars to community access

See how pharmacists turn pharmacogenomic results into safer prescribing—overcoming reimbursement, EHR, and equity barriers to scale testing in community pharmacies.

Phase 3 findings from the VIKTORIA-1 trial demonstrated clinically meaningful progression-free survival improvements with gedatolisib-based regimens in patients with PIK3CA-mutant HR+/HER2– advanced breast cancer.

Metabolic dysfunction-associated steatotic liver disease (MASLD) remains largely underdiagnosed and asymptomatic, creating major opportunities for pharmacists to drive early identification, lifestyle intervention, and metabolic risk management.

This approval marks the first high-efficacy B-cell depletion therapy approved for pediatric patients 10 years and older.

Treatment with zenocutuzumab-zbco led to an overall response rate of 36.8% for a duration ranging from 2.8 to 12.9 months.

Ivermectin, vitamin D, and zinc are being recommended on social media as treatment for hantavirus—despite a lack of evidence.

This review examines evidence on changes in muscle mass with incretin-based therapies and focuses on current and emerging strategies to preserve and enhance skeletal muscle mass.

Psilocybin-assisted psychotherapy significantly increased cocaine abstinence rates and reduced relapse risk in patients with cocaine use disorder.

A recent report of liver failure in a patient receiving orforglipron has renewed attention on the long-term safety monitoring of GLP-1 receptor agonists.

Explore updates around hantavirus outbreak and FDA controversies.

Forrest N. Ridgway, PharmD, BCOP, discusses health misinformation, AI-generated medical advice, wellness culture, and the controversial therapies patients are bringing into the clinic.

Effective real-world management of cytokine release syndrome (CRS) and immune effector cell–associated neurotoxicity syndrome (ICANS) is critical to safely delivering CAR T-cell therapies and bispecific antibodies.

Advanced lung cancer inflammation index (ALI) predicts 3‑month recovery after thrombolysis for acute ischemic stroke, with low ALI signaling higher risk.

University of Arizona pharmacy interns who received mentorship and engaged in pharmacist-level tasks report greater satisfaction and perceived professional readiness, highlighting a need to restructure internships as longitudinal, competency-based experiences.

The ACCESS trial found that expanding hematopoietic cell transplant eligibility through mismatched unrelated donors increased racial, ethnic, and socioeconomic diversity among recipients.

Study data show that extended endocrine therapy after 5 years reduces late recurrence in premenopausal breast cancer, with benefits varying by tumor subtype.

Emerging synthetic opioids known as orphines are entering the illicit drug supply with extreme potency and detection challenges.

Expanding education, safety responsibilities, and patient support roles are elevating the importance of pharmacy technicians in cancer care.

Pharmacists guide evidence-based medication care as AI, regulation shifts, and new therapies rise.

ENVISION trial shows mitomycin intravesical solution after TURBT delivers durable control in recurrent NMIBC, with 72% event-free at 24 months.

Education, safety protocols, and evolving responsibilities are transforming the role of pharmacy technicians in cancer care.

Pharmacy Times interviews Renee’ Acosta, R.Ph., M.S., on how pharmacy technicians can recognize when patients should be referred to a pharmacist or physician instead of self-treating with OTC products, and how to help patients avoid risks associated with combination products such as duplicate ingredients.

Bispecific antibodies show strong efficacy in relapsed/refractory lymphoma and early promise in frontline combination settings.

A new oral GLP-1 therapy could reshape obesity treatment by improving access, convenience, and patient uptake compared with injectable options.